Bonanno A, Tonini G M, de Marinis S
Urol Int. 1978;33(4):213-21. doi: 10.1159/000280201.
The authors experimented Aloglutamol (an organic salt of aluminium) in uremic patients on dialysis to detect its phosphate-binding properties and study its use in the treatment of uremic osteodystropy. They report good results: predialysis Ca increased; serum PO4 and alcaline phosphatase levels decreased; Ca X PO4 was normalized; itch, muscular weakness and constipation decreased; no side-effects appeared, and the drug has a good taste. Therefore it is considered to be most useful in the treatment of hyperphosphatemia in uremia.
作者对正在接受透析的尿毒症患者试用了阿洛谷氨醇（一种铝的有机盐），以检测其结合磷酸盐的特性，并研究其在治疗尿毒症性骨营养不良中的应用。他们报告了良好的结果：透析前血钙升高；血清磷酸盐和碱性磷酸酶水平降低；钙磷乘积恢复正常；瘙痒、肌肉无力和便秘减轻；未出现副作用，且该药味道良好。因此，它被认为对治疗尿毒症高磷血症最为有效。
